SOURCE: NeuroInvestment

November 15, 2007 12:36 ET

Insomnia Treatments Reviewed by NeuroInvestment

CARDIFF, CA--(Marketwire - November 15, 2007) - NI Research today announced the release of the November issue of NeuroInvestment, which reviews and evaluates the coming generation of insomnia drugs. Insomnia is an undertreated diagnostic category, with only a small percentage of those suffering from insomnia utilizing any of the pharmaceutical options available, due largely to side effects and to concerns regarding dependency and tolerance. Ambien, in both its generic and newer extended release version from Sanofi-Aventis, has continued to be the dominant player in the insomnia market. Sepracor has achieved some success with Lunesta, success not shared by Takeda's Rozerem, handicapped as Rozerem was by a lack of effect upon sleep maintenance, and a terrible choice of product name. Neurocrine Biosciences' (NASDAQ: NBIX) indiplon had at one time looked to be the next huge insomnia drug, but Pfizer's mishandling of the NDA process eventually left Neurocrine with a short-acting version only. Next-generation GABA-A based drugs are being developed by Neurogen (NASDAQ: NRGN) and Evotec. In terms of other mechanisms, Vanda Pharmaceuticals hopes that VEC-162 can outdo its melatonin-targeting predecessor, Rozerem, while 5HT-2a drugs are in the clinic from Arena Pharmaceuticals, Intra-Cellular Therapies, and Lilly (from Hypnion), while Actelion has the first orexin-antagonist for insomnia. There is also a discussion regarding the inherent subjective advantages of GABA-A modulation in sleep induction.

The November issue also has pointed commentary regarding recent subprime performances by the FDA; Pfizer's largesse in rewarding executive nonperformance; and a discussion of whether Paion's stroke program is rescuable. There is also a focus review of the French neuroscience company Trophos SA.

Recent issues of NI have reviewed Alzheimer's and pain. Forthcoming issues will review programs in spinal cord therapy and the overall state of the CNS field.

About NeuroInvestment: NeuroInvestment is the independent, monthly review of the neurotherapeutics area. A one-year subscription is $1500, email or hardcopy. Add $250 for dual delivery, add $40 for airmail delivery outside North America. A three-month trial subscription is US$600.

To download an information and ordering form, go to: http://www.niresearch.com/Annualpuborder.pdf

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroInvestment since 1995, the Private CNS Company Review since 2003, and has added CNS 2007-8, an annual compendium of all neuro-oriented R&D programs organized by disorder. NI Research also provides inlicensing consultation and custom research for large and small pharmaceutical firms. NI Research has developed an unmatched information base regarding both publicly and privately held neuro-oriented companies.

Contact Information